Galena Biopharma Presents GALE-301/GALE-302 Phase 1b Data at the American College of Surgeons Clinical Congress 2016
20 oct. 2016 07h05 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology...
Galena Biopharma to Present NeuVax™ (nelipepimut-S) plus Trastuzumab Interim Safety Data at the European Society for Medical Oncology (ESMO) 2016 Congress
10 oct. 2016 07h05 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., Oct. 10, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology...
Galena Biopharma to Present NeuVax™ (nelipepimut-S) Interim Safety Data at the European Society for Medical Oncology (ESMO) 2016 Congress
29 sept. 2016 07h05 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and...
Galena Biopharma Presents GALE-301 Folate Binding Protein Expression Data at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
27 sept. 2016 16h05 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., Sept. 27, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and...
Galena Biopharma to Present at the Sachs Associates 16th Annual Biotech in Europe Forum
20 sept. 2016 07h05 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and...
Galena Biopharma to Present at the 2016 Aegis Growth Conference
14 sept. 2016 07h05 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and...
Galena Biopharma Presents Preclinical NeuVax™ (nelipepimut-S) Data in Ovarian and Pancreatic Cancer at the Progress in Vaccination Against Cancer (PIVAC) Conference
13 sept. 2016 09h50 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and...
Galena Biopharma Expands GALE-401 Intellectual Property Protection with Patent Issuance in Japan
12 sept. 2016 07h05 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and...
Galena Biopharma to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
09 sept. 2016 07h05 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and...
Galena Biopharma Reports Second Quarter 2016 Financial Results and Provides a Corporate Update
09 août 2016 16h05 HE
|
Galena Biopharma, Inc.
Advancing GALE-401 (Anagrelide CR) into a pivotal trial for the treatment of essential thrombocythemiaClosing NeuVax Phase 3 PRESENT trialNeuVax combination trials with trastuzumab continueWebcast...